购物车
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Topoisomerase
    (2)
  • ADCs (Antibody-Drug Conjugates)
    (1)
  • CD38
    (1)
  • Liver X Receptor
    (1)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 6-8周
    (1)
  • in stock
    (2)
TargetMol | Tags 通过 研究领域 筛选
  • 癌症
    (1)
  • 癌症研究
    (1)
  • 神经系统
    (1)
TargetMol | Tags 通过 应用 筛选
  • ELISA
    (2)
  • Functional assay
    (2)
  • FACS
    (1)
  • FCM
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "a-1062"的结果
筛选
搜索结果
TargetMol产品目录中 "

a-1062

"的结果
  • 抑制剂&激动剂
    6
    抑制剂&激动剂
  • 抗体抑制剂
    2
    抗体抑制剂
  • ADC/ADC相关
    1
    ADC/ADC相关
  • A-1062
    T264621821-13-2
    A-1062, a resolvase-binding inhibitor, inhibits resolvase binding to the res site.
    • ¥ 10600
    6-8周
    规格
    数量
  • AMG-424
    XmAb968
    T9901A-1062
    AMG-424 (XmAb968) 是一种针对CD38和CD3E的人类双特异性抗体 (bsAb)。 AMG-424 能杀死CD38阳性的癌细胞,刺激T细胞增殖并减少细胞因子释放。在骨髓侵袭性小鼠癌症模型中,AMG-424 显示出抗肿瘤活性,并在食蟹猴中诱发外周B细胞耗竭。该化合物可用于多发性骨髓瘤的研究。
    • ¥ 12000
    待询
    规格
    数量
  • Datopotamab deruxtecan
    德达博妥单抗, S-1062a, DS-1062, DS1062, Dato-DXd
    T397302238831-60-0
    Datopotamab deruxtecan (DS-1062) 是一种滋养层细胞表面抗原 2 (TROP2) 靶向抗体药物偶联物 (ADC),具有抗肿瘤活性。Datopotamab deruxtecan 在外周血淋巴细胞存在下诱导显着的抗体依赖性细胞毒性,可在异种移植模型中抑制肿瘤生长。
    • ¥ 10600
    现货
    规格
    数量
    TargetMol | Inhibitor Hot
  • UNC 1025
    T601971350549-36-8In house
    UNC 1062是一种高度选择性的酪氨酸激酶抑制剂,专门针对MERTK。该化合物有效抑制MERTK介导的下游信号传导,诱导细胞培养中的凋亡,减少软琼脂中的集落形成,并抑制黑色素瘤细胞的侵袭。值得注意的是,UNC1062对MERTK激酶活性的抑制作用强大,其IC50为1.1 nM,Morrison Ki为0.33 nM。它还在TAM家族内显示出特异性,其针对TYRO3和AXL的IC50值分别为60 nM和85 nM [1]。
    • ¥ 712
    现货
    规格
    数量
  • GLN-1062
    T16037224169-27-1
    GLN-1062 是 galantamine 的前体药物,在阿尔兹海默症中有研究价值。
    • ¥ 226
    现货
    规格
    数量
    TargetMol | Inhibitor Sale
  • SR 1903
    T356381414248-06-8
    SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg/kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity.References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019). SR 1903 is a modulator of retinoic acid receptor-related orphan receptor γ (RORγ) and liver X receptor (LXR).1 It is an inverse agonist of RORγ (IC50 = ~100 nM in a cell-based reporter assay) and an agonist of LXR. It also binds to peroxisome proliferator-activated receptor γ (PPARγ; IC50 = 209 nM) but does not activate it. SR 1903 (10 μM) inhibits LPS-induced expression of triggering receptor expressed on myeloid cells 1 (TREM-1) in RAW 264.7 cells. It also inhibits LPS-induced expression of the LXR target genes IL-6 and IL-33 and increases expression of ABCG1, FASN, and SCD-1 in RAW 264.7 cells. SR 1903 (20 mg/kg twice per day) reduces severity score in a mouse model of collagen-induced arthritis. It reduces blood glucose levels in a glucose tolerance test, serum levels of total cholesterol and LDL, body weight, and fat mass in a mouse model of high-fat diet-induced obesity. References1. Chang, M.R., Ciesla, A., Strutzenberg, T.S., et al. Unique polypharmacology nuclear receptor modulator blocks inflammatory signaling pathways. ACS Chem. Biol. 14(5), 1051-1062 (2019).
    • ¥ 938
    现货
    规格
    数量